Selective granulocyte and monocyte apheresis (GMA) as a non-pharmacological option,
has shown promising efficacy and higher safety in the treatment of patients with ulcerative
colitis (UC). The GMA can not only promote healing of intestinal mucosa and improve
the clinical remission rate, prolong the time of clinical alleviate [
[1]
], to reduce the recurrence rate, but also have certain effect to control the extra-intestinal
accompanying symptoms [
2
,
3
]. Compared with conventional therapy, GMA has shown promising efficacy and higher
safety in the treatment of patients with ulcerative colitis (UC). However, the efficacy
and safety in the Crohn's disease (CD) is controversial. Therefore, we report a meta-analysis
of randomized trials assessing the efficacy and safety of GMA for inflammatory bowel
disease (IBD).Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multi-centre controlled study.Dig Liver Dis. 2008; 40: 433-440
- Pyoderma gangrenosum with ulcerative colitis successfully treated by the combination of granulocyte and monocyte adsorption apheresis and corticosteroids.Intern Med. 2016; 55: 25-30
- Successful treatment for erythema nodosum and peripheral arthritis associated with ulcerative colitis by granulocyte and monocyte apheresis: a report of a case.Jpn J Gastroenterol. 2002; 99: 951-955
- The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis.Int J Colorectal Dis. 2011; 26: 999-1007
- Efficacy and safety of granulocyte and monocyte adsorption apheresis for ulcerative colitis: a meta-analysis.Dig Liver Dis. 2013;
- Adsorptive granulocyte/monocyte apheresis for the maintenance of remission in patients with ulcerative colitis: a prospective randomized, double blind, sham-controlled clinical trial.Gut Liver. 2012; 6: 427-433
- Intermittent granulocyte and monocyte apheresis versus mercaptopurine for maintaining remission of ulcerative colitis: a pilot study.Ther Apher Dial. 2012; 16: 213-218
- A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease.Gut. 2013; 62: 1288-1294
- Granulocyte/monocyte adsorptive apheresis in moderate to severe ulcerative colitis — effective or not?.Digestion. 2015; 92: 39-44
- An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease.BMC Gastroenterol. 2015; 15
- Combination therapy with intensive granulocyte and monocyte adsorptive apheresis plus adalimumab: therapeutic outcomes in 5 cases with refractory Crohn's disease.Case Rep Gastroenterol. 2012; 6: 765-771
Article info
Publication history
Published online: September 07, 2016
Accepted:
August 24,
2016
Received:
August 23,
2016
Identification
Copyright
© 2016 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
